Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0003320,
umls-concept:C0017262,
umls-concept:C0026473,
umls-concept:C0031437,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0441889,
umls-concept:C0443199,
umls-concept:C0871261,
umls-concept:C1515655,
umls-concept:C1515926,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911684,
umls-concept:C2911692
|
pubmed:issue |
2
|
pubmed:dateCreated |
1995-12-15
|
pubmed:abstractText |
We investigated, via multicolor flow cytometry, the in vivo effects of colony-stimulating factors (CSFs) on cell size, frequencies, and expression of surface antigens on peripheral blood monocytes from melanoma patients treated concurrently with CSFs and tumor-specific monoclonal antibody (mAb) R24. Recombinant human macrophage colony-stimulating factor (rhM-CSF) increased cell size, relative percentages of monocytes, percentages of CD14+, HLA-DQ+, CD11b+, and CD16+ monocytes, and cell-surface expressions of HLA-DR and CD11b; rhM-CSF also up-regulated cell-surface expression of CD14 on CD14brightCD16- monocytes. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) increased cell size, percentages of CD14+, HLA-DQ+, and CD11b+ monocytes, and cell-surface expressions of HLA-DR, HLA-DQ, CD11b, and CD58. Relative percentages of monocytes and CD16+ cells and cell-surface expression of CD14 on CD14brightCD16- monocytes decreased. In addition, monocytes derived from patients treated with rhM-CSF showed functional activity when assayed in vitro for antibody-dependent cellular cytotoxicity (ADCC). During treatment and coincident with increased CD16 expression, monocytes derived from rhM-CSF patients had enhanced levels of cytotoxicity towards melanoma target cells compared to healthy controls and to patients treated with rhGM-CSF.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Macrophage Colony-Stimulating Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0196-4763
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
103-10
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7587740-Antibodies, Monoclonal,
pubmed-meshheading:7587740-Antibodies, Neoplasm,
pubmed-meshheading:7587740-Antigens, Neoplasm,
pubmed-meshheading:7587740-Antigens, Surface,
pubmed-meshheading:7587740-Cell Size,
pubmed-meshheading:7587740-Combined Modality Therapy,
pubmed-meshheading:7587740-Flow Cytometry,
pubmed-meshheading:7587740-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:7587740-Humans,
pubmed-meshheading:7587740-Immunophenotyping,
pubmed-meshheading:7587740-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:7587740-Melanoma,
pubmed-meshheading:7587740-Monocytes,
pubmed-meshheading:7587740-Recombinant Proteins
|
pubmed:year |
1995
|
pubmed:articleTitle |
Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
|
pubmed:affiliation |
Department of Medicine, UCLA School of Medicine 90095-1745, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|